Form 8-K Mirum Pharmaceuticals, For: Jun 17
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Mirum Pharamceuticals (MIRM) PT Raised to $62 at Evercore ISI
June 17, 2024 3:22 PM EDTEvercore ISI analyst Gavin Clark-Gartner raised the price target on Mirum Pharamceuticals (NASDAQ: MIRM) to $62.00 (from $53.00) while maintaining a Outperform rating.
The analyst comments "MIRM is one of the rare, profitable smallcaps in our coverage based on their base business alone (which... More
Mirum Pharamceuticals (MIRM) PT Raised to $64 at Citi
June 17, 2024 3:00 PM EDTCiti analyst David Lebowitz raised the price target on Mirum Pharamceuticals (NASDAQ: MIRM) to $64.00 (from $38.00) while maintaining a Buy rating.
The analyst comments "In todays call, Mirum highlighted that volixibat performance in both PSC & PBC beat expectations. Early best-in-disease itch... More
Mirum Pharamceuticals (MIRM) PT Raised to $57 at Morgan Stanley
June 17, 2024 1:37 PM EDTMorgan Stanley analyst Michael E Ulz raised the price target on Mirum Pharamceuticals (NASDAQ: MIRM) to $57.00 (from $53.00) while maintaining a Overweight rating.
The analyst comments "Interim Ph2b volixibat results better than expected, as robust activity observed in PBC and blinded analysis in... More
Stifel Reiterates Buy Rating on Mirum Pharamceuticals (MIRM)
June 17, 2024 10:28 AM EDTStifel analyst Dae Gon Ha reiterated a Buy rating and $48.00 price target on Mirum Pharamceuticals (NASDAQ: MIRM)
The analyst comments "Today's interim analyses for volixibat studies - primary biliary cholangitis (PBC; VANTAGE) and primary sclerosing cholangitis (PSC; VISTAS) - offer promising... More
Citi Reiterates Buy Rating on Mirum Pharamceuticals (MIRM)
June 17, 2024 8:41 AM EDTCiti analyst David Lebowitz reiterated a Buy rating and $38.00 price target on Mirum Pharamceuticals (NASDAQ: MIRM)
The analyst comments "This morning, Mirum shared positive interim updates from volixibats Ph2b VISTAS and VANTAGE trials in primary sclerosing cholangitis (PSC) and primary biliary cholangitis... More
